Intelligence Platform
Patents
Browse 93 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 10730854
Therapeutically active compounds and their methods of use
granted patentUS 10717764
Therapeutically active compounds and their methods of use
granted patentUS 10711314
Methods for diagnosing IDH-mutant cell proliferation disorders
granted patentUS 10695352
Combination therapy for treating malignancies
granted patentUS 10689414
Therapeutically active compounds and their methods of use
granted patentUS 10689375
Compounds and their methods of use
granted patentUS 10653710
Combination therapy for treating malignancies
granted patentUS 10640534
Therapeutically active compositions and their methods of use
granted patentUS 10632114
Pyruvate kinase activators for use in therapy
granted patentUS 10610125
Methods and compositions for cell-proliferation-related disorders
granted patentUS 10449184
Pharmaceutical compositions of therapeutically active compounds
granted patentUS 10434105
Therapeutically active compounds and their methods of use
granted patentUS 10414740
Glutaminase inhibitors and method of use
granted patentUS 10376510
2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of ca
granted patentUS 10329298
Inhibitors of cellular metabolic processes
granted patentUS 10294215
Therapeutically active compounds and their methods of use
granted patentUS 10202339
Therapeutic compounds and compositions
granted patentUS 10201543
Therapeutically active compounds and their methods of use
granted patentUS 10188656
Methods of treatment of malignancies
granted patentUS 10172864
Therapeutically active compounds and their methods of use
granted patentUS 10137130
Methods of treatment of malignancies
granted patentUS 10111878
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitor
granted patentUS 10105369
Therapeutically active compounds and their methods of use
granted patentUS 10101331
Methods of evaluating patients using E-cadherin or vimentin
granted